NUCLEAR EXPORT INHIBITOR
Xpovio is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who have been treated with at least two previous therapies. Xpovio is also referred to by its drug name, selinexor.
Xpovio is a member of a class of drugs called nuclear export inhibitors. Xpovio is believed to work by blocking the XPO1 protein, which allows tumor suppressor proteins to accumulate in cancer cells, causing cell death.
How do I take it?
Prescribing information states that Xpovio should be taken orally on days 1 and 3 of each week.
Xpovio comes in the form of a tablet.
The FDA-approved label for Xpovio lists common side effects including fatigue, nausea, vomiting, diarrhea, constipation, decreased appetite, and fever.
Rare but serious side effects listed for Xpovio include low platelet counts, low white blood cell counts, serious infections, neurologic side effects, severe nausea and vomiting, cataracts, and decreased blood sodium levels.
For more details about this treatment, visit:
Xpovio — Karyopharm
Selinexor (Xpovio) — OncoLink